NCT05858450

This Study Intends to Describe the Characteristics of Patients Given the Pfizer-BioNTech Bivalent mRNA COVID-19 Vaccine and Any Commercially Available Influenza Vaccines at the Same Time Versus at Different Times.

Investigating Uptake and Subsequent Health Outcomes Associated With Pfizer-BioNTech Bivalent COVID-19/Influenza Vaccine Concomitant Administration Using a Claims-based Real-world Data Source in the US

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 3,442,996 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study intends to describe the characteristics of patients given the Pfizer-BioNTech bivalent mRNA COVID-19 vaccine and any commercially available influenza vaccines at the same time versus at different times.

Conditions

• Influenza, Human
• COVID-19

Interventions

Type	Name	Description
BIOLOGICAL	Comirnaty	COMIRNATY is an active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.
BIOLOGICAL	Quadrivalent Influenza Vaccine	Quadrivalent Influenza Vaccine is a class of vaccines indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccines

Timeline

• Start date: 2023-05-05
• Primary completion: 2023-05-12
• Completion: 2023-05-12
• First posted: 2023-05-15
• Last updated: 2024-09-20
• Results posted: 2024-09-20

Locations

1 site across 1 country: United States